NVIDIA expands Microsoft partnership with Blackwell GPUs for AI infrastructure
Investing.com - Leerink Partners raised its price target on AstraZeneca (NASDAQ:AZN) to $87.00 from $85.00 on Monday, while maintaining an Outperform rating on the pharmaceutical giant following its third-quarter earnings report.
AstraZeneca reported total product sales of $14.365 billion for the third quarter of 2025, exceeding consensus estimates of $14.031 billion by approximately 2%. The company’s oncology segment drove the revenue beat, with strong performances from key products including Enhertu, Truqap, Imfinzi/Imjudo, Tagrisso, Calquence, and Datroway.
The pharmaceutical company reiterated its full-year 2025 guidance, projecting high single-digit percentage revenue growth and low double-digit percentage growth in core earnings per share. AstraZeneca also confirmed it remains on track to achieve its mid-30s percentage core operating margin target for 2026 and its $80 billion revenue target for 2030.
AstraZeneca disclosed details about its agreement with the U.S. government regarding pricing and tariffs, which includes a three-year tariff exemption and government support for price equalization across wealthy markets. The company plans to expand its U.S. manufacturing footprint with a $4.5 billion investment in Virginia.
Leerink Partners noted that its updated price target does not yet incorporate the value of several Phase 3 opportunities in AstraZeneca’s pipeline, including baxdrostat/dapagliflozin for chronic kidney disease and heart failure, and laroprovstat (AZD0780) for dyslipidemia.
In other recent news, AstraZeneca reported positive results from its Phase III NATRON trial for FASENRA (benralizumab), showing a 65% reduction in disease worsening for patients with hypereosinophilic syndrome compared to placebo. The company also received approval from the European Commission for Koselugo (selumetinib) to treat symptomatic, inoperable plexiform neurofibromas in adults with neurofibromatosis type 1, following a successful KOMET Phase III trial. Additionally, AstraZeneca’s stock rating was upgraded to Buy by Jefferies, citing the undervaluation of its oncology portfolio and biopharmaceutical pipeline. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of Saphnelo (anifrolumab) for subcutaneous self-administration in patients with systemic lupus erythematosus. In corporate governance news, Euan Ashley, a non-executive director at AstraZeneca, has been appointed to the board of DexCom, effective in 2025. These developments reflect AstraZeneca’s ongoing efforts in advancing its pharmaceutical portfolio and corporate strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.